Table 1 Clinical data of patients with MDR-AB pneumonia
Death group (n = 45) | Survival group (n = 121) | P value | |
|---|---|---|---|
Data | |||
Age (Y) | 81 (72.5–85.5) | 64 (50–75.5) | < 0.001 |
Gender | 29 (64.4%) | 82 (67.8%) | 0.686 |
APACHEII Scores | 20 (20, 22.5) | 20 (16, 33) | 0.094 |
Underlying diseases | |||
Liver diseases | 7 (15.6%) | 12 (9.9%) | 0.31 |
Neurovascular disease | 18 (40.0%) | 53 (43.8%) | 0.66 |
Kidney diseases | 16 (35.6%) | 14 (11.6%) | < 0.001 |
Diabetes | 11 (24.4%) | 16 (13.2%) | 0.082 |
Pulmonary diseases | 23 (51.1%) | 37 (30.6%) | 0.014 |
Heart disease | 27 (60.0%) | 41 (33.9%) | 0.002 |
Immune abnormalities | 4 (8.9%) | 14 (11.6%) | 0.621 |
Treatment | |||
Treatment delay | 7 (15.6%) | 19 (15.7%) | 0.982 |
Mechanical ventilation | 38 (84.4%) | 65 (53.7%) | < 0.001 |
Invasive catheterization | 44 (95.6%) | 77 (63.6%) | < 0.001 |
Carbapenems | 43 (95.6%) | 92 (76.0%) | 0.004 |
Tigecycline | 20 (44.4%) | 98 (81.0%) | < 0.001 |
Sulbactam | 20 (44.4%) | 80 (66.1%) | 0.011 |